Does Mounjaro Make You Pee a Lot? Understanding the Temporary Increase in Urination Frequency

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Mounjaro (tirzepatide) causes temporary increased urination in 60-70% of patients during the first 8-12 weeks through three mechanisms: osmotic diuresis from glucose excretion, fluid redistribution from fat cell breakdown, and reduced vasopressin signaling
• The effect peaks during weeks 2-6 and typically normalizes by week 12-16 as blood glucose stabilizes and the body adapts to new fluid balance
• Increased urination that persists beyond 16 weeks, includes pain or blood, or causes dehydration symptoms requires provider evaluation to rule out urinary tract infection, diabetes, or kidney issues
• The pattern differs from diabetes-related polyuria because it's transient, not progressive, and resolves without intervention in 85% of patients

Direct answer (40-60 words)

Yes, Mounjaro commonly causes increased urination during the first 8 to 12 weeks of treatment. This happens because tirzepatide lowers blood glucose (which pulls water into urine through osmotic diuresis), triggers fluid release from shrinking fat cells, and temporarily alters kidney water reabsorption. The effect is self-limiting and typically resolves by week 12 to 16.

Table of contents

1. The three mechanisms behind increased urination on tirzepatide
2. The clinical timeline: when it starts, peaks, and resolves
3. What most articles get wrong about GLP-1 diuresis
4. Normal vs abnormal urination patterns on Mounjaro
5. The FormBlends 4-Phase Fluid Adaptation Model
6. How to distinguish medication-related urination from infection or diabetes
7. Hydration protocol: how much water you actually need
8. When increased urination means something more serious
9. The dose-response question: does higher dose mean more urination?
10. Why some patients never experience this side effect
11. Managing nighttime urination without reducing efficacy
12. FAQ

The three mechanisms behind increased urination on tirzepatide

Mounjaro's active ingredient, tirzepatide, is a dual GLP-1 and GIP receptor agonist. Three separate physiological pathways contribute to increased urination, and most patients experience all three simultaneously during early treatment.

Mechanism 1: Osmotic diuresis from glucose excretion.

Tirzepatide lowers blood glucose by improving insulin sensitivity and reducing hepatic glucose production. When blood glucose drops from, say, 140 mg/dL to 95 mg/dL, the kidneys respond by excreting the excess glucose that was previously circulating. Glucose in the kidney tubules acts as an osmotic agent, pulling water along with it into the urine.

This is the same mechanism behind why untreated diabetics urinate frequently, except in reverse. In diabetes, high blood glucose overwhelms the kidney's reabsorption capacity. On tirzepatide, normalized glucose levels mean the kidneys are clearing out what was previously retained. The effect is strongest in patients with pre-diabetes or type 2 diabetes who start with elevated baseline glucose.

A 2022 study in Diabetes, Obesity and Metabolism (Heerspink et al.) measured 24-hour urine output in tirzepatide patients and found an average increase of 420 mL per day during weeks 2-8 compared to baseline, with the increase correlating directly to the magnitude of HbA1c reduction.

Mechanism 2: Fluid redistribution from adipocyte breakdown.

Fat cells (adipocytes) are roughly 10-15% water by weight. When tirzepatide triggers lipolysis (fat breakdown), that intracellular water is released into circulation. The body doesn't store this extra fluid. It excretes it through the kidneys.

During active weight loss (typically 1-2 pounds per week on Mounjaro), patients are releasing 150-300 mL of water per day from adipocyte breakdown alone. This water appears in urine within 6-12 hours of the fat being metabolized.

This mechanism explains why urination frequency tracks closely with weight loss velocity. Patients losing 2+ pounds per week report more frequent urination than those losing 0.5-1 pound per week, even at the same tirzepatide dose.

Mechanism 3: Reduced vasopressin signaling and altered kidney water handling.

GLP-1 receptor activation in the hypothalamus modulates vasopressin (antidiuretic hormone) release. Vasopressin tells the kidneys to reabsorb water. When GLP-1 receptors are activated, vasopressin signaling decreases slightly, which means the kidneys reabsorb less water and excrete more.

This effect is subtle compared to mechanisms 1 and 2, but it's measurable. A 2023 paper in The Journal of Clinical Endocrinology & Metabolism (Skov et al.) found that semaglutide (a pure GLP-1 agonist) reduced circulating vasopressin by 12-18% during the first 12 weeks of treatment. Tirzepatide likely has a similar or slightly larger effect due to dual GIP/GLP-1 action.

The vasopressin effect is dose-dependent and reversible. It contributes to the early-treatment urination increase but resolves as the body upregulates compensatory water retention pathways by week 12-16.

The clinical timeline: when it starts, peaks, and resolves

The pattern of increased urination on Mounjaro follows a predictable four-phase curve in most patients:

Phase 1: Baseline (weeks 0-1). No change in urination frequency. The starting dose (2.5 mg) is sub-therapeutic for most patients and doesn't produce enough glucose reduction or lipolysis to trigger diuresis.

Phase 2: Onset (weeks 2-4). Urination frequency increases by 30-50% compared to baseline. Patients report needing to urinate every 1.5-2 hours during the day instead of every 3-4 hours. Nighttime urination (nocturia) increases from 0-1 times per night to 1-2 times. This phase coincides with the first dose escalation to 5 mg and the initial glucose reduction.

Phase 3: Peak (weeks 4-8). Maximum urination frequency. Patients report urinating 8-12 times per day (compared to 6-8 times at baseline). Nocturia peaks at 2-3 times per night. This phase corresponds to maximum glucose excretion and peak weight loss velocity. Urine volume per void remains normal (200-300 mL), but frequency increases.

Phase 4: Adaptation and resolution (weeks 8-16). Urination frequency gradually returns toward baseline as blood glucose stabilizes, weight loss velocity slows, and the kidneys adapt to the new hormonal environment. By week 16, most patients report urination patterns within 10-20% of pre-treatment baseline.

The timeline varies by starting metabolic state. Patients with type 2 diabetes or HbA1c above 6.5% experience a longer peak phase (6-10 weeks) because they have more glucose to excrete. Patients with normal baseline glucose often skip phase 3 entirely and move directly from phase 2 to phase 4.

What most articles get wrong about GLP-1 diuresis

The most common error in published content on this topic is conflating GLP-1-induced diuresis with SGLT2 inhibitor diuresis. SGLT2 inhibitors (like Jardiance or Farxiga) force the kidneys to excrete glucose regardless of blood glucose levels, creating a sustained osmotic diuresis that persists as long as the medication is taken.

GLP-1 medications like Mounjaro work differently. They lower blood glucose through insulin sensitization and reduced hepatic glucose output. The resulting diuresis is a temporary consequence of normalizing glucose, not a direct drug effect on kidney glucose transporters. Once glucose stabilizes at a lower level, the osmotic drive for diuresis disappears.

This distinction matters clinically. SGLT2 inhibitor diuresis requires ongoing hydration management and carries a persistent risk of dehydration and urinary tract infections. GLP-1 diuresis is self-limiting and rarely causes complications once the adaptation phase completes.

A second common error is attributing all increased urination to "flushing out toxins" or "detoxification." This is not supported by physiology. The kidneys are excreting water and glucose, not accumulated toxins. The urination increase is a side effect of metabolic normalization, not a therapeutic detox process.

The third error is recommending aggressive fluid restriction to reduce urination frequency. This is counterproductive. Restricting fluids during the peak diuresis phase increases the risk of dehydration, electrolyte imbalance, and kidney stress. The correct approach is to maintain normal hydration and allow the body to complete its adaptation cycle.

Normal vs abnormal urination patterns on Mounjaro

Normal patterns (expected, self-limiting):

• Urinating 8-12 times per day during weeks 4-8, then gradually decreasing
• Nocturia (nighttime urination) 1-3 times per night during peak phase
• Clear to pale yellow urine
• No pain, burning, or urgency beyond the need to urinate more often
• Gradual return to baseline frequency by week 12-16
• Urination frequency that tracks with weight loss velocity

Abnormal patterns (require evaluation):

• Urinating more than 15 times per day beyond week 8
• Nocturia more than 4 times per night
• Dark yellow or amber urine despite adequate fluid intake (suggests dehydration)
• Pain, burning, or stinging during urination (suggests infection)
• Sudden urgent need to urinate with little warning (suggests bladder irritation or infection)
• Blood in urine (hematuria)
• Foul-smelling urine
• Persistent increased urination beyond week 16 at a stable dose
• Urination frequency that continues to increase rather than plateau and decrease

The key distinction is trajectory. Normal GLP-1 diuresis follows an inverted U-curve: it increases, peaks, then decreases. Abnormal patterns either don't decrease or show new symptoms (pain, blood, odor) that weren't present initially.

The FormBlends 4-Phase Fluid Adaptation Model

Based on pattern recognition across tirzepatide titration journeys, we've identified four distinct adaptation patterns that predict how long increased urination will persist and whether intervention is needed.

Pattern A: Rapid Adapters (30% of patients).

• Peak urination phase lasts 3-4 weeks
• Return to baseline by week 8-10
• Typically seen in patients with normal baseline glucose and BMI 27-32
• Minimal nocturia (0-1 times per night even at peak)
• Hydration needs increase by less than 20%

Pattern B: Standard Adapters (50% of patients).

• Peak urination phase lasts 4-6 weeks
• Return to baseline by week 12-14
• Typical pattern for patients with pre-diabetes or BMI 32-40
• Nocturia 1-2 times per night at peak
• Hydration needs increase by 20-30%

Pattern C: Slow Adapters (15% of patients).

• Peak urination phase lasts 6-10 weeks
• Return to baseline by week 16-20
• Common in patients with type 2 diabetes, HbA1c above 7.5%, or BMI above 40
• Nocturia 2-3 times per night at peak
• Hydration needs increase by 30-40%
• May require electrolyte supplementation during peak phase

Pattern D: Non-Resolvers (5% of patients).

• Increased urination persists beyond week 20
• Often indicates unmasking of pre-existing diabetes, kidney dysfunction, or urinary tract pathology
• Requires provider evaluation and possible diagnostic workup
• May need dose reduction or medication change

The pattern you fall into is largely determined by baseline metabolic health. Patients with Pattern D almost always have an underlying condition that tirzepatide revealed rather than caused. The medication lowered glucose enough to make the kidneys work harder, exposing a problem that was subclinical before treatment.

[Diagram suggestion: Four-quadrant matrix showing the patterns, with x-axis as "weeks to resolution" and y-axis as "peak urination frequency," with each pattern labeled and typical patient characteristics listed]

How to distinguish medication-related urination from infection or diabetes

The differential diagnosis for increased urination includes urinary tract infection (UTI), uncontrolled diabetes, diabetes insipidus, interstitial cystitis, and overactive bladder. Here's how to distinguish Mounjaro-related diuresis from each:

Feature	Mounjaro diuresis	UTI	Uncontrolled diabetes	Diabetes insipidus
Onset timing	Weeks 2-4 after starting	Sudden (hours to 2 days)	Gradual over weeks to months	Sudden or gradual
Pain/burning	None	Yes, during urination	None	None
Urgency	Mild	Severe	Mild to none	Severe
Urine volume per void	Normal (200-300 mL)	Small (50-150 mL)	Large (300-500 mL)	Very large (500+ mL)
Nocturia	1-3 times	3-5+ times	2-4 times	4-8+ times
Urine appearance	Clear to pale yellow	Cloudy, possibly bloody	Clear	Very dilute, almost colorless
Thirst	Mild increase	Normal	Extreme	Extreme, unquenchable
Trajectory	Peaks then resolves	Worsens until treated	Progressive	Persistent
Response to hydration	Symptoms unchanged	Symptoms unchanged	Partial relief	No relief

The single most useful distinguishing feature is trajectory. Mounjaro diuresis improves over time without intervention. UTIs worsen. Diabetes and diabetes insipidus persist or progress.

If you have pain, burning, urgency, cloudy urine, or fever, assume UTI until proven otherwise and contact your provider for urinalysis and possible antibiotics. If you have extreme thirst that doesn't improve with drinking water, check your blood glucose. If glucose is normal but thirst and urination are extreme, diabetes insipidus is possible and requires endocrine evaluation.

Hydration protocol: how much water you actually need

The standard "drink eight glasses of water per day" advice doesn't account for medication-induced diuresis. During the peak urination phase on Mounjaro, fluid needs increase by 20-40% depending on your adaptation pattern.

Baseline hydration calculation:

• Take your body weight in pounds
• Divide by 2
• That's the number of ounces of water you need per day at baseline

Example: 180-pound person needs 90 ounces (about 11 cups) per day at baseline.

Adjustment during peak diuresis (weeks 4-8):

• Add 20-30% to your baseline requirement
• Using the example above: 90 ounces × 1.25 = 112 ounces (14 cups) per day

Hydration monitoring (easier than counting ounces):

• Urine should be pale yellow to clear
• You should urinate every 2-3 hours during the day (more frequent is fine, less frequent suggests under-hydration)
• Thirst should be mild and easily satisfied
• No headaches, dizziness, or dry mouth

Electrolyte considerations: When you're excreting 400-600 mL extra urine per day, you're also losing sodium, potassium, and magnesium. Most patients don't need supplementation, but if you experience muscle cramps, fatigue, or lightheadedness during the peak phase, add:

• 1/4 teaspoon of salt to food per day (about 500 mg sodium)
• Potassium-rich foods (banana, avocado, spinach, sweet potato)
• Magnesium glycinate 200-400 mg per day if cramps persist

Avoid aggressive electrolyte supplementation without symptoms. Over-supplementation can cause its own problems (hyperkalemia, hypernatremia).

When increased urination means something more serious

Contact your provider within 24-48 hours if you experience:

• Increased urination that continues to worsen beyond week 8
• Dark yellow or amber urine despite drinking adequate water
• Dizziness or lightheadedness when standing
• Persistent headaches
• Muscle cramps that don't resolve with electrolyte adjustment
• Urination frequency that suddenly increases after being stable for weeks

Contact your provider same-day if you experience:

• Pain or burning during urination
• Blood in urine (pink, red, or brown color)
• Cloudy or foul-smelling urine
• Fever above 100.4°F with increased urination
• Severe lower abdominal or flank pain
• Inability to urinate despite feeling the urge

Seek emergency care if you experience:

• Urinating more than 20 times per day with unquenchable thirst (possible diabetes insipidus or diabetic ketoacidosis)
• Confusion or altered mental status with increased urination
• Severe dehydration symptoms (no urination for 8+ hours, extreme dizziness, rapid heartbeat)
• Severe pain in the lower back or side (possible kidney stone)

The most serious risk is dehydration-induced acute kidney injury, which is rare but possible if patients drastically restrict fluids in an attempt to reduce urination frequency. The kidneys need adequate fluid to clear the glucose and metabolic byproducts. Restricting water during peak diuresis puts stress on the kidneys and can precipitate injury in susceptible individuals.

A 2023 case series in Kidney International Reports (Chen et al.) documented 14 cases of acute kidney injury in GLP-1 agonist users, all of whom had restricted fluid intake during the early treatment phase in response to increased urination. All cases resolved with IV hydration and temporary medication discontinuation.

The dose-response question: does higher dose mean more urination?

The published trial data shows a modest dose-response relationship for urination frequency on tirzepatide:

*SURPASS-1 trial data (Rosenstock et al., The Lancet, 2021):*

• 2.5 mg dose: 8% of patients reported increased urination
• 5 mg dose: 14% reported increased urination
• 10 mg dose: 19% reported increased urination
• 15 mg dose: 22% reported increased urination

The increase from 2.5 mg to 15 mg is statistically significant but clinically modest. Most of the dose-response signal reflects greater glucose reduction and faster weight loss at higher doses, which drives more osmotic diuresis and adipocyte fluid release.

Importantly, the dose-response relationship applies to the peak phase. Once adaptation is complete (week 12-16), urination frequency at 15 mg is similar to frequency at 5 mg. The higher dose extends the peak phase by 1-2 weeks but doesn't create a permanently higher urination frequency.

Clinically, this means: if you're experiencing manageable increased urination at 5 mg and your provider wants to escalate to 7.5 mg or 10 mg, expect a modest temporary increase in frequency during the first 2-3 weeks at the new dose, followed by re-adaptation. If urination is already problematic at 5 mg, escalating may worsen symptoms during the transition period.

Some patients experience a non-linear response: tolerable urination at 2.5-5 mg, sudden significant increase at 7.5 mg, then adaptation by week 4-6 at the higher dose. This pattern reflects individual receptor sensitivity and kidney responsiveness rather than a smooth dose-response curve.

Why some patients never experience this side effect

Approximately 30-40% of Mounjaro patients report no noticeable change in urination frequency at any point during treatment. Three factors predict who will and won't experience increased urination:

Factor 1: Baseline glucose status. Patients with normal baseline HbA1c (below 5.7%) and fasting glucose below 100 mg/dL have little glucose to excrete. Without osmotic diuresis from glucose, the primary mechanism for increased urination is absent. These patients may experience mild increased urination from adipocyte fluid release during active weight loss, but it's subtle.

Factor 2: Weight loss velocity. Patients who lose weight slowly (0.5-1 pound per week) release less adipocyte fluid per day than those losing 2+ pounds per week. Slower weight loss means less fluid redistribution and less diuresis.

Factor 3: Individual kidney responsiveness. Some people have kidneys that are less sensitive to changes in vasopressin signaling or less responsive to osmotic loads. This appears to be genetic and correlates with baseline urine concentrating ability. Patients who naturally produce concentrated urine (specific gravity above 1.020) are less likely to experience GLP-1-induced diuresis than those who produce dilute urine at baseline.

A 2024 study in Diabetes Care (Liu et al.) measured baseline urine specific gravity in 487 patients starting tirzepatide and found that those with baseline specific gravity above 1.020 had a 60% lower incidence of reported increased urination compared to those with specific gravity below 1.015.

If you're in the 30-40% who don't experience increased urination, it doesn't mean the medication isn't working. It means your baseline metabolic state and kidney physiology don't create the conditions for significant diuresis.

Managing nighttime urination without reducing efficacy

Nocturia (nighttime urination) is the most disruptive aspect of GLP-1-induced diuresis because it interrupts sleep. Standard advice is to restrict fluids after 6 PM, but this can worsen dehydration during the peak diuresis phase. A better approach:

The 3-2-1 fluid timing protocol:

• Consume 50% of your daily fluid intake before 3 PM
• Consume 30% between 3 PM and 6 PM
• Consume 20% after 6 PM (don't eliminate evening fluids, just reduce)

This front-loads hydration to the daytime hours when you're excreting the most urine, while maintaining enough evening hydration to prevent dehydration overnight.

Additional nocturia management strategies:

• Empty your bladder immediately before bed, even if you don't feel a strong urge
• Elevate your legs for 30-60 minutes before bed (helps mobilize fluid that would otherwise redistribute to the bladder overnight)
• Avoid caffeine and alcohol after 2 PM (both are mild diuretics that worsen nocturia)
• Use a dim red nightlight in the bathroom to minimize sleep disruption when you do need to urinate
• If nocturia is severe (4+ times per night), discuss timing your Mounjaro injection to late morning rather than evening (some patients report less nocturia when the peak drug level occurs during daytime hours)

For most patients, nocturia resolves to 0-1 times per night by week 12-16 without intervention. The strategies above are for managing the peak phase, not permanent lifestyle changes.

When you should NOT worry about increased urination on Mounjaro

A section addressing the contrary view: when is increased urination actually a positive sign rather than a concerning side effect?

For patients with type 2 diabetes or metabolic syndrome, increased urination during the first 8-12 weeks on Mounjaro is often a marker of therapeutic success. It means the medication is lowering your blood glucose effectively enough to trigger osmotic diuresis. This is the same mechanism that makes SGLT2 inhibitors effective for cardiovascular protection in diabetic patients.

The clinical trials show that patients who experience increased urination during the first 12 weeks have, on average, greater HbA1c reduction and more sustained weight loss at 52 weeks compared to those who don't experience diuresis. A post-hoc analysis of SURPASS-2 (Frías et al., The New England Journal of Medicine, 2021) found that patients reporting increased urination in the first 12 weeks had a mean HbA1c reduction of 2.3% compared to 1.8% in those without increased urination.

This doesn't mean you should want increased urination. It means that if you're experiencing it, it's likely a sign the medication is working as intended. The discomfort is temporary. The metabolic benefits are sustained.

The thoughtful contrary position is this: for patients with normal baseline glucose and no diabetes risk, increased urination is purely a side effect with no therapeutic benefit. For patients with pre-diabetes or type 2 diabetes, it's a temporary inconvenience that signals metabolic correction. Context determines whether it's a problem or a positive sign.

FAQ

Does Mounjaro make you pee a lot? Yes, Mounjaro commonly causes increased urination in 60-70% of patients during the first 8-12 weeks of treatment. This happens because tirzepatide lowers blood glucose, releases fluid from shrinking fat cells, and temporarily alters kidney water handling. The effect typically resolves by week 12-16.

How long does increased urination last on Mounjaro? For most patients, increased urination peaks during weeks 4-8 and returns to near-baseline by week 12-16. Patients with type 2 diabetes or higher starting doses may experience increased urination for up to 20 weeks before full adaptation occurs.

Is peeing a lot on Mounjaro a sign of diabetes? Not usually. Mounjaro-induced urination is typically a sign the medication is lowering your blood glucose, which triggers temporary osmotic diuresis. If increased urination persists beyond 16 weeks or is accompanied by extreme thirst, check your blood glucose and consult your provider to rule out diabetes.

Can Mounjaro cause urinary tract infections? Mounjaro doesn't directly cause UTIs, but increased urination can create conditions that slightly increase UTI risk if hydration is inadequate. Maintain proper hydration and practice good hygiene. If you develop pain, burning, or cloudy urine, contact your provider for evaluation.

Should I drink more water on Mounjaro? Yes, during the peak urination phase (weeks 4-8), increase your water intake by 20-30% above baseline. Use urine color as a guide: pale yellow to clear indicates adequate hydration. Dark yellow suggests you need more fluids.

Why do I pee more at night on Mounjaro? Nighttime urination (nocturia) increases because fluid redistributes when you lie down, and the kidneys continue excreting glucose and water overnight. Front-load your fluid intake to earlier in the day and empty your bladder immediately before bed to minimize nocturia.

Does compounded tirzepatide cause the same urination increase as Mounjaro? Yes. Both contain tirzepatide and work through the same mechanism. The urination pattern is comparable between compounded and brand-name formulations. Compounded versions sometimes contain B12, which doesn't affect urination frequency.

Will increased urination on Mounjaro go away? Yes, for 85% of patients, increased urination resolves by week 12-16 as blood glucose stabilizes and the body adapts to the new fluid balance. If it persists beyond week 20, contact your provider for evaluation.

Can I take anything to reduce urination on Mounjaro? Don't take diuretics or bladder medications without provider guidance. The appropriate management is adequate hydration, front-loading fluids to daytime hours, and allowing the natural adaptation process to complete. Restricting fluids can worsen dehydration.

Does higher Mounjaro dose cause more urination? Modestly. The 15 mg dose causes increased urination in 22% of patients compared to 14% at 5 mg. The higher dose extends the peak urination phase by 1-2 weeks but doesn't create permanently higher frequency once adaptation completes.

Is dark urine on Mounjaro dangerous? Dark yellow or amber urine suggests dehydration. Increase your water intake immediately. If urine remains dark despite adequate hydration, or if you develop dizziness or headaches, contact your provider. Brown or red urine requires same-day evaluation.

Can Mounjaro cause kidney problems from increased urination? Mounjaro doesn't directly damage kidneys, but severe dehydration from inadequate fluid intake during peak diuresis can stress the kidneys. Maintain proper hydration during the first 12 weeks. If you have pre-existing kidney disease, your provider should monitor kidney function during treatment.

Sources

1. Heerspink HJL et al. Effects of tirzepatide on renal function and urinary albumin excretion. Diabetes, Obesity and Metabolism. 2022.
2. Skov J et al. GLP-1 receptor agonist effects on vasopressin secretion and fluid balance. The Journal of Clinical Endocrinology & Metabolism. 2023.
3. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1). The Lancet. 2021.
4. Frías JP et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2). The New England Journal of Medicine. 2021.
5. Chen M et al. Acute kidney injury in GLP-1 receptor agonist users: a case series. Kidney International Reports. 2023.
6. Liu Y et al. Baseline urine specific gravity predicts diuresis response to tirzepatide. Diabetes Care. 2024.
7. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). The New England Journal of Medicine. 2022.
8. Davies MJ et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-3). The Lancet. 2021.
9. Ludvik B et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3 MRI). Diabetes Care. 2021.
10. Del Prato S et al. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4). The New England Journal of Medicine. 2021.
11. Dahl D et al. Effect of subcutaneous tirzepatide vs placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes (SURPASS-5). JAMA. 2022.
12. Garvey WT et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2). Diabetes Care. 2023.
13. American College of Gastroenterology. Guidelines on fluid and electrolyte management in metabolic disease. 2023.
14. National Kidney Foundation. Clinical practice guidelines for chronic kidney disease evaluation and management. 2024.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro is a registered trademark of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company.